TGF-β1 serves as a driving factor for EMT and functions as an important immunosuppressant, reducing tumor sensitivity to the immune system by inhibiting the differentiation of cytotoxic T lymphocytes (CTLs) and increasing the production of regulatory T lymphocytes (Treg) [138,139]. The gene discussed is TGFB1; the disease is neoplasm.